← Back to Search

Monoclonal Antibodies

Treatment for Neurofibromatosis

Phase 1 & 2
Waitlist Available
Research Sponsored by NaviFUS Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights

Study Summary

This trial will test the safety and effectiveness of using Bevacizumab along with microbubble-mediated Focused Ultrasound (FUS) in patients with recurrent glioblastoma. Bevaciz

Who is the study for?
This trial is for patients with recurrent Glioblastoma Multiforme (rGBM) who have already undergone treatments like surgery, radiotherapy, and chemotherapy with temozolomide. It's not specified here, but typically participants should be in stable health otherwise.Check my eligibility
What is being tested?
The study is testing the safety and effectiveness of Bevacizumab (BEV), a standard treatment for rGBM, when combined with a new technique using microbubbles and Focused Ultrasound (FUS). This combination aims to improve outcomes for patients.See study design
What are the potential side effects?
While specific side effects are not listed here, Bevacizumab commonly includes risks such as high blood pressure, bleeding problems, fatigue, headaches and possibly allergic reactions related to infusion.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events (AEs)
Secondary outcome measures
6-month Progression-Free Survival (PFS-6)
Clinical Benefit Rate (CBR)
Corticosteroid Consumption
+6 more

Find a Location

Who is running the clinical trial?

NaviFUS CorporationLead Sponsor
6 Previous Clinical Trials
56 Total Patients Enrolled
NaviFUS US LLCUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there currently ongoing efforts to enroll participants for this clinical trial?

"Information available on clinicaltrials.gov indicates that patient recruitment is not active for this particular study. The trial was originally listed on July 1st, 2024 and last updated on March 19th, 2024. Despite the current inactivity in patient enrollment for this specific research project, it is noteworthy that there are a total of 3330 other trials actively open to accepting patients at present."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
2024. "Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06329570.
All > Cancer > Neurofibromatosis
~7 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top